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Background: There have been few randomized control trials comparing the incidence of stent fracture and
primary patency among different self-expanding nitinol stents to date. The SMART™ CONTROL stent (Cordis
Corp, Miami Lakes, Florida, United States) has a peak-to-valley bridge and inline interconnection, whereas the
COMPLETE™-SE stent (Medtronic Vascular, Santa Rosa, California, United States) crowns have been configured
to minimize crown-to-crown interaction, increasing the stent's flexibility without compromising radial
strength. Further, the 2011 ESC (European society of cardiology) guidelines recommend that dual antiplatelet
therapy with aspirin and a thienopyridine such as clopidogrel should be administered for at least one month
after infrainguinal bare metal stent implantation. Cilostazol has been reported to reduce intimal hyperplasia
and subsequent repeat revascularization. To date, there has been no randomized study comparing the safety
and efficacy of two different antiplatelet regimens, clopidogrel and cilostazol, following successful
femoropopliteal stenting.
Methods/Design: The primary purpose of our study is to examine the incidence of stent fracture and
primary patency between two different major representative self-expanding nitinol stents (SMART™ CONTROL
versus COMPLETE™-SE) in stenotic or occlusive femoropopliteal arterial lesion. The secondary purpose is to
examine whether there is any difference in efficacy and safety between aspirin plus clopidogrel versus aspirin
plus cilostazol for one month following stent implantation in femoropopliteal lesions. This is a prospective,
randomized, multicenter trial to assess the efficacy of the COMPLETE™-SE versus SMART™ CONTROL stent for provisional
stenting after balloon angioplasty in femoropopliteal arterial lesions. The study design is a 2x2 randomization design
and a total of 346 patients will be enrolled. The primary endpoint of this study is the rate of binary restenosis in the
treated segment at 12 months after intervention as determined by catheter angiography or duplex ultrasound.
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Discussion: This trial will provide powerful insight into whether the design of the COMPLETE™-SE stent is more
fracture-resistant or effective in preventing restenosis compared with the SMART™ CONTROL stent. Also, it will
determine the efficacy and safety of aspirin plus clopidogrel versus aspirin plus cilostazol in patients undergoing stent
implantation in femoropopliteal lesions.
Trial registration: Registered on 2 April 2012 with the National Institutes of Health Clinical Trials Registry
(ClinicalTrials.gov identifier# NCT01570803).Background
Percutaneous transluminal balloon angioplasty for athero-
sclerotic femoropopliteal lesions has a high primary success
rate of 90% without complications. However, restenosis
rates are 60% within a year and restenosis rates increase to
70% for interventions on the superficial femoral artery
where the lesion length is over 10 cm. Because of this, sur-
gical treatment for restenosis was recommended by the
Inter-Society Consensus for the Management of Peripheral
Arterial Disease (TASC) in 2000 [1]. Later, a stainless steel
stent was developed for atherosclerotic femoropopliteal le-
sions and adopted for clinical use. However, five random-
ized controlled trials failed to demonstrate any benefit of a
stainless steel stent over balloon angioplasty alone [2-6].
The development of a nitinol stent has resulted in an
innovative change in the interventional approach. Nit-
inol stents have contributed greatly to the lowering of
restenosis rates and have also been shown to be super-
ior to balloon angioplasty alone [7-10]. Based on these
findings, the TASC II practice guidelines were devel-
oped [11]. Due to the development of the nitinol stent,
restenosis rates have been reduced following femoro-
popliteal stenting. However, the use of a nitinol stent is
only recommended when the result of a balloon angio-
plasty is not satisfactory as the ‘provisional concept’,
and restenosis rates are still high in long lesions, such
as TASC type C and D lesions.
The superficial femoral artery is the longest artery in
human body and is located between two flexion points,
the femoral joint and knee joint. Several types of forces
are regularly applied to this vessel, such as flexion, lon-
gitudinal or lateral compression, torsion and others. Be-
cause of such features of the femoropopliteal artery,
stent fracture can occur and several studies reported
that the stent fracture can be a clinically significant fac-
tor in restenosis [12,13].
Other reported risk factors for in-stent restenosis in-
clude stent length and the number of implanted stents
(overlapping stenting), stent design, severity of calcifica-
tion of the vessel, and stent elongation that may occur
during deployment [14,15]. Recently developed stent
designs focus on reducing the rate of stent fracture to
prevent restenosis. In the FESTO study [12], it was hy-
pothesized that differences in nitinol stent designs affectstent fracture and restenosis rates. In this study, the
Luminexx stent showed the highest stent fracture rate
while the SMART™ stent showed the lowest stent frac-
ture rate, with the fracture rate increasing with lesion
length. Additionally, it was concluded that stent fracture
is closely related to in-stent restenosis or reocclusion.
Based on an in vitro study, Stefan Müller-Hülsbeck
et al. claimed that there are differences in the perform-
ance of seven different types of stents in a mechanical
fatigue test designed to predict stent fracture and, based
on this, they also claimed that differences in stent de-
sign may play an important role in development of stent
fracture [16].
Currently, several manufacturers produce nitinol stents
for atherosclerotic femoropopliteal lesions, and all of them
may differ in incidence of stent structure. As mentioned
earlier, there are several laboratory, retrospective, or regis-
tered clinical studies on restenosis that compare the effect
of bending, compression, and torsion on stent fracture
rates in a variety of stent designs or types. However, well-
designed, prospective, randomized, controlled clinical tri-
als that compare restenosis rates among different stent
types have rarely been conducted. Until now, the SUPER-
SL study [14] is the only literature available for a random-
ized comparative study examining differences in primary
patency rates between the SMART™ stent and Luminexx
stent in long superficial femoral artery lesions (lesion
length 5 to 22 cm). There is no randomized comparative
study that compares two different types of nitinol stents
in terms of stent fracture and primary patency rates in
an Asian population, especially among new-generation
nitinol stents.
The SMART™ CONTROL stent (Cordis Corp, Miami
Lakes, Florida, United States) and the COMPLETE™-SE
stent (Medtronic Vascular, Santa Rosa, California, United
States) are both open-cell slotted tube designs, but they
differ in connection shape between cell and cell or
between crown and crown, and number of bridges.
Because of such differences in design, Medtronic claim
that the COMPLETE™-SE stent has exceptional elasti-
city and flexibility compared to other nitinol stents,
without decreasing radial force.
Further, according to the 2011 ESC (European society
of cardiology) guidelines [17], dual antiplatelet therapy
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one month after the implantation of a bare metal stent
into an atherosclerotic femoropopliteal lesion. Clinical
research on the effectiveness of cilostazol in atheroscler-
otic peripheral arterial disease have been frequently re-
ported. Recently, meta-analysis results have also reported
that cilostazol is effective in reducing intermittent claudi-
cation [18]. However, while there are small-scale [19] or
retrospective studies [20] that include a partial comparison
showing a reduction in restenosis or revascularization
rates in patients stented for femoropopliteal artery disease,
there are few studies involving a large number of patients.
Additionally, there are no randomized studies comparing
the long-term effects of clopidogrel and cilostazol on redu-
cing restenosis or revascularization rates in patients follow-
ing femoropopliteal artery self-expanding nitinol stenting.
In this study, we will compare the incidence of stent
fracture and primary patency between SMART™ CONTROL
and COMPLETE™-SE stents. In addition, we would like
to ascertain whether there are differences in efficacy
and safety between aspirin plus clopidogrel versus as-
pirin plus cilostazol in patients undergoing stent im-
plantation in femoropopliteal lesions.
Method/Design
Study objectives, hypothesis and design
The primary purpose of our study is to examine and
compare the incidence of stent fracture and primary pa-
tency between two different nitinol stents (SMART™
CONTROL versus COMPLETE™-SE) in stenotic or oc-
clusive femoropopliteal arterial lesions. The secondary
purpose is to ascertain whether there is difference in ef-
ficacy and safety between aspirin plus clopidogrel versus
aspirin plus cilostazol in patients undergoing stent im-
plantation in femoropopliteal lesions. This is a prospect-
ive, randomized, multicenter trial to assess the efficacyFigure 1 Flow chart of the enrolled patients. ABI: Ankle-brachial index;of the COMPLETE™-SE versus SMART™ CONTROL
stent by provisional stenting after balloon angioplasty for
stenotic or occlusive femoropopliteal arterial lesions.
The protocol of the trial has been registered with the
National Institutes of Health Clinical Trials Registry
(registration number: NCT01570803) and a brief flow
chart of the whole study is summarized in Figure 1.
Study population
Patients at least 20 years of age who have moderate or
severe intermittent claudication or critical limb ischemia
(Rutherford score of 2 to 6, except any patient who has
undergone or plans to take major amputation) will be
screened for study enrollment. A patient will be enrolled
if they meet all of the inclusion and have none of the ex-
clusion criteria. Inclusion criteria consist of clinical and
anatomical criteria. The clinical criteria includes symp-
tomatic peripheral-artery disease with moderate to severe
claudication (Rutherford score of 2 to 3), chronic critical
limb ischemia with resting ischemic pain (Rutherford
score of 4), or chronic critical limb ischemia with ischemic
ulcers (Rutherford score of 5 to 6), and patient must pro-
vide written informed consent. The anatomical criteria in-
cludes stenosis of more than 50% of, or occlusion of the
ipsilateral femoropopliteal artery, patent (≤50% stenosis)
ipsilateral iliac artery, or concomitantly treatable ipsilateral
iliac lesions (≤30% residual stenosis), and at least one pa-
tent (less than 50% stenosis) tibioperoneal run-off vessel.
Patients meeting any of the following criteria will be ex-
cluded from the study: failure to provide written informed
consent; a history of major bleeding within prior two
months; known hypersensitivity or contraindication to any
of the following medications: heparin, aspirin, clopidogrel,
cilostazol, or contrast agent; acute limb ischemia; previous
bypass surgery or stenting of the ipsilateral femoropopli-
teal artery; untreated inflow disease of the ipsilateral pelvicPCI: Percutaneous coronary intervention.
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undergone major amputation (amputation of above the
ankle) or major amputation is planned or required; pa-
tients with a life expectancy of less than one year due to
comorbidities.
Randomization and interventions
Prior to the intervention, aspirin and clopidogrel will be
administered at least 12 hours before the procedure.
Prior to the intervention, 70 to 100 units/kg of unfractio-
nated heparin will be administered. Endovascular inter-
ventions will be carried out percutaneously, by placing a
6–8-Fr sheath at the femoral artery via an antegrade ap-
proach or a contralateral crossover technique. In selected
cases, a retrograde approach (from the distal superficial
femoral artery, popliteal artery, or pedal arteries) and/or
brachial approach will be allowed.
Diagnostic angiography will be performed in two differ-
ent views at least 30 to 45° apart to evaluate the structure
of the lesion. Femoropopliteal and tibial arteries will be
visually checked for the presence of distal lesions. To
document the precise location of the lesion and the site of
the intervention, we will recommend the use of a ruler. In
cases of total occlusion, both intraluminal and subintimal
methods of recanalization will be allowed. In procedure,
the use of other special devices will be allowed; for ex-
ample reentry device OUTBACK™ catheter (Cordis Corp,
Miami Lakes, Florida, United States) and Offroad catheter
(Boston Scientific, Natick, MA, United states), CTO de-
vices Frontrunner (Cordis Corp, Miami Lakes, Florida,
United States) and Truepath (Boston Scientific, Natick,
MA, United states), and atherectomy devices such as
SilverHawk™ and TurboHawk™ (Covidien, Plymouth,
Minnesota). After the successful passage of the guide-
wire, predilation of the target lesion with an optimally
sized balloon will be performed prior to stent implant-
ation. Recommended, minimal balloon dilation time is
120 seconds. Then, if there is a residual pressure gradi-
ent of ≥10 mmHg, residual stenosis of ≥30%, or flow-
limiting dissection, the balloon angioplasty results will
be considered as suboptimal results. Subsequently, web-
based randomization for stent selection will be performed.
Patients will be stratified into two groups, less than 15 cm
or more than 15 cm, according to lesion length. Random
allocation of the patients will be performed via a web-
based computerized program separately managed at the
Cardiovascular Intervention Research Institute (CIRI),
Korea University Guro Hospital, Seoul, Republic of Korea.
Patients will be randomized in a 1:1 manner according
to two different stents (SMART™ CONTROL versus
COMPLETE™-SE). The stents will be implanted to ex-
tend 10 mm proximally and distally from the margins of
the target lesion with luminal narrowing of ≥50%. Spot
stenting or full lesion coverage will be decided at physician’sdiscretion. When multiple stents are required, the margins
of the stents should be overlapped by at least 10 mm. Ad-
juvant post-dilation after the stenting will be performed
strictly within the stented segment, with up to 10% over-
sizing of the post-dilation balloon.
All ipsilateral iliac arterial lesions should be treated
with angioplasty and/or stenting concomitantly and re-
sidual stenosis should be less than 50%. Treatment of
tibioperoneal lesions is recommended only in cases of
critical limb ischemia. There should exist at least one pa-
tent (<50% stenosis) tibioperoneal run-off vessel with
good antegrade flow.
A final angiography will be performed after the interven-
tion in both groups, with the use of the same angles and
magnifications used in the baseline angiograms. Simultan-
eously, reference vessel diameter (RVD), minimal luminal
diameter (MLD), percent diameter stenosis, and acute gain
should be measured. The reference vessel diameter will
be obtained from averaging 5-mm segments proximal
and distal to the lesion. Technical success will be de-
fined as the successful access and deployment of the
stent and less than 30% diameter residual stenosis after
the revascularization.
For the post-procedural medication, aspirin 100 mg
and clopidogrel 75 mg will be administered once daily
for one month. Then, patients of each group will be ran-
domized by web-based randomization to receive either
clopidogrel 75 mg or cilostazol 100 mg once daily in
addition to aspirin 100 mg for at least 11 months in a
1:1 manner.
After enrollment and index procedure, clinical follow-
up will be planned at 1, 6, and 12 months to evaluate
clinical outcomes and ankle-brachial index score. Also,
all patients will be recommended to have a follow-up
catheter angiography or duplex ultrasound at 12 months
according to local clinical practice. The incidence of stent
fracture and binary patency will be assessed by plain X-ray
and quantitative femoral angiography. The investigators
will be urged to follow up on patients, either by office
visits or by telephone contacts, as necessary. Patient ad-
herence to the study drug and side effects will be checked
and monitored at every outpatient visit. The decision of
drug discontinuation will be discussed and checked under
the physician’s recommendation.
Outcome measures
The primary endpoint of this study is the rate of binary
restenosis (stenosis of at least 50% of the luminal diam-
eter) or PSVR (peak systolic velocity ratio) ≥2.5 or 0
(PSVR = peak systolic velocity within the area of stenosis
divided by peak systolic velocity in a normal adjacent
proximal artery segment) in the treated segment at 12
months after the intervention as determined by cath-
eter angiography or duplex ultrasound. The secondary
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and major stent fracture (moderate or severe stent frac-
ture); 2) stent fracture rate according to fracture grade
(minor, moderate, severe); 3) limb salvage rate free of
above-the-ankle amputation; 4) sustained clinical im-
provement rate at 12-month follow-up; 5) repeated tar-
get lesion revascularization (TLR) rate; 6) repeated
target extremity revascularization (TER) rate; 7) total
reocclusion rate; 8) comparison of angiograph variables
consisting of late loss and restenosis rate; 9) ankle-
brachial index (ABI) at 12 months; 10) the rate of major
adverse cardiovascular events (MACE) composed of all-
cause death, myocardial infarction, repeat percutaneous
coronary intervention (PCI), and stroke at 12 months;
11) incidence of geographic miss during stent deployment
due to jumping and/or elongation; 12) rate of binary re-
stenosis or PSVR ≥2.5 or 0 according to clopidogrel and
cilostazol; and 13) major bleeding rate between clopido-
grel and cilostazol group. The detailed definitions are
summarized in the Appendix.
Statistical analysis
Sample size calculation
From previous studies, including ABSOLUTE [7], FAST
[8], and ASTRON [9], recurrence rates in femoropopliteal
lesions after one year were 32%, 34.4%, and 37%, respect-
ively - approximately 35% on average. The recurrence rate
for the SMART™ CONTROL stent was 34.8% in the
SUPER-SL study - a multicenter, randomized controlled
trial that compared two self-expanding nitinol stents, the
SMART™ CONTROL and Luminexx stents, in femoropo-
pliteal lesions [14]. So far, there are limited data on the
one-year primary patency rate of the COMPLETE™-SE
stent. Based on previous research results, the SMART™
CONTROL stent group will be the control group, and the
COMPLETE™-SE stent group will be the experimental
group. Based on the SUPER-SL results, the one-year pri-
mary patency of the SMART™ CONTROL stent is esti-
mated to be 65% and the one-year primary patency of the
COMPLETE™-SE stent is estimated to be 80%, which is
higher than that of the SMART™ CONTROL stent. Recur-
rence will be defined as more than 50% restenosis or total
occlusion under invasive angiography, or if invasive angi-
ography is not performed, PSVR ≥2.5 when evaluated with
duplex ultrasound. The statistical significance level is set
at 5%, the power of test is set as 80%, and the randomization
ratio is set as 1:1. Test for proportion and chi-square method
are used. Using standard sample size formula, it was calcu-
lated that 138 patients per group are needed for a total of
346 patients, after accounting for a 20% dropout rate.
Statistical analysis
Categorical variables will be expressed as delivery rate
when comparing baseline features between the SMART™CONTROL and COMPLETE™-SE stent groups or the
clopidogrel and cilostazol groups, and for categorical
variables, comparisons between groups will use the chi-
square or Fisher’s exact test. Continuous variables will
be expressed as mean ± standard deviation, and for con-
tinuous variables, comparisons between groups will use
the Student’s t-test. The primary and secondary end-
points will be analyzed using both intention-to-treat
analysis (all subjects assigned to a treatment group) and
per-protocol analysis (only subjects completed the treat-
ment protocol). Study endpoints will also be analyzed
per patient. For the primary endpoint (12-month binary
restenosis rate) comparisons of the two patient groups
will use the chi-square or Fisher’s exact test. At the end
of the 12 months, cumulative restenosis rates will be cal-
culated. All secondary endpoint analysis will be per-
formed using the Student’s t-test, chi-square test, or
Fisher’s exact test. Also, clinical outcomes such as revascu-
larization of the target vessel, death, major cardiovascular
events including myocardial infarction and cerebral infarc-
tion, and limb salvage rates will be analyzed using Kaplan-
Meier survival estimates and a comparison of the groups
will be performed using the log-rank test. A P value <0.05
is considered to be statistically significant. In order to
evaluate the risk factors for recurrence, defined as resten-
osis or total occlusion, univariate and multivariate logistic
regression analysis will be performed. Present research has
concluded that there will be a very low chance of missing
data to cause bias, and therefore, missing data for the
major endpoints will be excluded from the analysis data.
For repeated measurements for the secondary endpoints,
last observation carried forward (LOCF) can be applied.
The SPSS 20.0 (SPSS Inc, Chicago, Illinois, United States)
statistics program will be used for all analysis.
Trial organization
Executive committee
The Executive Committee will be composed of the study
chairperson and selected members among the investiga-
tors. This committee is responsible for overseeing the
administrative progress of the study and will approve the
final trial design and protocol issued to the Data and
Safety Monitoring Board (DSMB) and the clinical sites.
This committee will also be responsible for reviewing
the final results, determining the methods of presenta-
tion and publication, and selection of secondary projects
and publications by members of the Steering Committee.
The Executive Committee also holds the right to modify
or stop the study prematurely based on recommendations
from the DSMB.
Data Safety Monitoring Board (DSMB)
The frequency of the DSMB meetings will be deter-
mined prior to study commencement. Additionally, the
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to suspect that safety is an issue. The DSMB is respon-
sible for making recommendations regarding any safety
or compliance issues throughout the course of the study
and may recommend to the Executive Committee to
modify or stop the study. However, all final decisions
regarding study modifications rest with the Executive
Committee.
All cumulative safety data will be reported to the
DSMB and reviewed on an ongoing basis throughout en-
rollment and follow-up periods to ensure patient safety.
Every effort will be made to allow the DSMB to conduct
an unbiased review of patient safety information. All
DSMB reports will be made available to the appropriate
agencies upon request but will otherwise remain strictly
confidential.
Prior to the DSMB’s first review of the data, the DSMB
charter will be drafted. The DSMB will develop a con-
sensus understanding of all trial endpoints and defini-
tions used in the event adjudication process. All DSMB
reports will remain strictly confidential, but will be made
available to the regulatory body upon request.
Clinical Event Adjudication Committee (CEAC)
The Clinical Events Committee (CEAC) is comprised of
interventional and non-interventional cardiologists who
are not involved in the study. The CEAC is charged
with the development of specific criteria used for the
categorization of clinical events and clinical endpoints
in the study which are based on protocol. At the onset
of the trial, the CEAC will establish explicit rules out-
lining the minimum amount of data required and the
algorithm followed in order to classify a clinical event.
All members of the CEAC will be blinded to the pri-
mary results of the trial. The CEAC will meet regularly
to review and adjudicate all clinical events. The CEAC
will also review and rule on all deaths that occur
throughout the trial.
Data coordination and site management
Data coordination and site management services will be
performed at the Cardiovascular Center of the Korea
University Guro Hospital.
Ethical approval
This study has been approved by the institutional review
boards of investigator’s centers (Soonchunhyang University
Cheonan Hospital, reference number SCHCA 2013-02-
006; Korea University Guro Hospital, reference number
MD12018; Kwandong University Myongji Hospital, refer-
ence number 13-030; Human Research Kunkuk University
Chungju Hospital, reference number 2013-006; Kangwon
National University Hospital, reference number 2013-01-
004; Samsung Seoul Medical Center, reference numberSMC 2013-02-075-001; Incheon Sa-Rang Hospital, refer-
ence number 2013-4; St Carollo Hospital, reference number
SCH 2013-119; Chonnam University Hospital, reference
number CNUH-2013-021; Chungbuk National University
Hospital, reference number CBNUH 2013-02-001-001;
Konyang University Hospital, reference number 13-05;
IS Incheon Hanlim Hospital, reference number 2013-
3; Gwangju Bohoon Hospital, reference number 2013-5-1;
Cheongju St Mary's Hospital, reference number IRB-5A-1;
Seoul National University Boramae Hospital, reference
number 20130806/26-2013-70/082; Deajeon Catholic
Medical Center, reference number DIRB-00110_1-006;
Soonchunhyang University Bucheon Hospital, reference
number 2013-11-003; Hanmaeum Medical Center, refer-
ence number MD2013-0006; Hallym University Chuncheon
Sacred Heart Hospital, reference number 2014-64). The
investigator will obtain their written approval before being
allowed to conduct and participate in the study. The in-
vestigator is also responsible for fulfilling any conditions
of approval imposed by the institutional review board,
such as regular reporting, study timing, and so on. The in-
vestigator will provide the Sponsor with copies of such ap-
provals and reports.Discussion
Endovascular revascularization is a minimally invasive
therapy for the treatment of patients with femoropopli-
teal arterial disease who suffer from intermittent claudi-
cation or critical limb ischemia. Technology has rapidly
evolved during the last decade and there is now a grow-
ing body of experience in the treatment of even complex
cases [21]. However, the femoropopliteal artery remains
a challenging area for endovascular treatment. During
movements, various forces are exerted on this vessel.
Therefore the use of intravascular stents in the femoro-
popliteal artery continues to be controversial due to the
potential for compression and fracture. As mentioned
previously, recent stent design improvements focus on
decreasing stent fracture rates which can negatively im-
pact patency rates by rearranging strut alignment.Rationale of randomized trials comparing two different
generation stents
The factors associated with in-stent restenosis after stent
implantation in femoropopliteal lesion have been known
to be very various; patient characteristics, lesion character-
istics, and so on. Recently, various self-expandable nitinol
stents have been manufactured by many companies and
they each claim that the design of their product is superior
in terms of radial force, stent deformity or fracture, and
deployment system. As aforementioned, several studies
have shown that stent fracture might be associated with
in-stent restenosis. Also geographic miss, due to stent
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associated with stent fracture and in-stent restenosis [22].
On the other hand, the design of self-expandable nit-
inol stents might be different depending on the time
they were developed; first-generation nitinol stents (such
as Luminexx™ and SMART™) showed a remarkably high
rate of stent strut fracture [22]. A second generation of
slotted tube nitinol stents has been developed. These
stents have better flexibility by reducing the number of
connections between cells or crowns and configuring
the spiral orientation of these interconnections [23]. Sev-
eral studies have reported that these nitinol stents are
more fracture-resistant and more flexible, with some of
them providing superior patency rate (such as Life™ and
Everflex™) [22,24].
However, an important limitation to their studies is
that they were non-randomized studies of relative small
sample size or were confined to in vitro. As of yet, a
multicenter randomized controlled trial for direct com-
parison of stent fracture and primary patency between
two different nitinol stents has not been done except for
one study: SMART™ versus Luminexx stent (Super SL
trial) [14]. SMART™ and Luminexx stents have been
classified as first generation self-expandable nitinol
stents. The Complete-SE stent (Figure 2A) of Medtronic
company is different to the SMART™ CONTROL stent
(Figure 2B) of Cordis company in that the configuration
of interconnection of Complete-SE has peak-to-peak con-
nection, fewer bridges (4 versus 6) and struts (24 versus
36), a larger cell size, and a more spiral orientation of
interconnection, compared to the SMART™ CONTROL
stent. On the other hand, the SMART™ CONTROL stent
has the peak-to-valley bridge, more bridges, a smaller cell
size, and inline interconnection. Medtronic have claimedFigure 2 Comparison for stent design. A; Complete-SE stent design, B; S
SMART™ CONTROL stent in that the configuration of interconnection of Co
struts (24 versus 36), a larger cell size, and a more spiral orientation of inter
hand, the SMART™ CONTROL stent has the peak-to-valley bridge, more bridComplete-SE has been configured to minimize cell-to-cell
and bridge-to-bridge interaction, increasing the stent’s
flexibility without compromising radial strength. We made
the hypothesis that the design of the Complete-SE stent
might be more fracture-resistant or effective for in-stent
restenosis, compared with the SMART™ CONTROL
stent.
Rationale of randomized trials comparing clopidogrel and
cilostazol following femoropopliteal stenting
To date, in many previous reports, dual antiplatelet ther-
apy consisting of aspirin and clopidogrel has proven to
decrease the incidence of cardiovascular death, myocar-
dial infarction, and revascularization without an increase
in major bleeding in patients who have undergone PCI
regardless of stent type (bare metal stent or drug-eluting
stent) [25-27]. In 2011 the ESC guidelines recommended
dual antiplatelet therapy with aspirin and a thienopyri-
dine such as clopidogrel for at least one month after
infra-inguinal bare metal stent implantation (Class I,
Level C). However, there has been no definite evidence
or guideline for the optimal antiplatelet agent after stent
implantation beyond one month later [17]. There have
been many studies for the efficacy of thienopyridines in
peripheral arterial disease. In the Swedish Ticlopidine
Multicenter Study (STIMS) 687 patient of intermittent
claudication were treated with ticlopidine or placebo,
and the incidence of fatal or non-fatal myocardial infarc-
tion and stroke was reduced in the ticlopidine group
[28]. A randomized blinded trial of clopidogrel versus
aspirin in patients at risk of ischemic events (CAPRIE)
demonstrated that clopidogrel was better in treating per-
ipheral artery disease than aspirin (relative risk reduction
in composite end point: 23.8%) [29]. Based on this trial,MART™ CONTROL stent design. Complete-SE stent is different to
mplete-SE has peak-to-peak connection, fewer bridges (4 versus 6) and
connection, compared to the SMART™ CONTROL stent. On the other
ges, a smaller cell size, and inline interconnection.
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mic events in patients with peripheral artery disease by
the United State Food and Drug Administration [29].
Clopidogrel is effective in reducing cardiovascular events
in a subgroup of patients with symptomatic peripheral
arterial disease, with or without other clinical evidence
of cardiovascular disease [11]. In the CHARISMA (Clo-
pidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance) trial, the
large number of patients with documented prior myo-
cardial infarction, ischemic stroke, or symptomatic per-
ipheral artery disease appeared to derive significant
benefit from dual antiplatelet therapy with clopidogrel
plus aspirin beyond aspirin alone [30]. In the CASPAR
(Results of the randomized, placebo-controlled clopido-
grel and acetylsalicylic acid in bypass surgery for periph-
eral arterial disease) trial, the combination of clopidogrel
plus aspirin did not improve limb or systemic outcomes
in the overall population of peripheral artery disease pa-
tients requiring below-knee bypass grafting [31]. Sub-
group analysis suggests that clopidogrel plus aspirin
confers benefit in patients receiving prosthetic grafts
(Hazard ratio: 0.65; 95% CI: 0.45-0.95; P = 0.025) without
significantly increasing risk of major bleeding [31]. With
the potential benefit of cilostazol on vascular function
in vitro, there have been several previous efforts to prove
the efficacy of cilostazol in patients undergoing endovas-
cular therapy or stent implantation in peripheral arterial
disease. For example, Soga et al. and Iida et al. have re-
ported that cilostazol may improve amputation-free sur-
vival and limb salvage rate after endovascular therapy
for infrainguinal disease in patients with critical limb is-
chemia and intermittent claudication [19,32-34]. Also,
they have demonstrated that cilostazol reduced resten-
osis after superficial femoral artery stenting with a self-
expandable nitinol stent and it seems to be more effect-
ive in patients who are at a high risk of restenosis [35].
However, very few trials have not effectively or properly
addressed the direct comparison for the efficacy and
safety between clopidogrel and cilostazol. This trial is
designed to evaluate the efficacy and safety between as-
pirin plus clopidogrel versus aspirin plus cilostazol in pa-
tients undergoing stent implantation in femoropopliteal
lesions.
In conclusion, we still do not know whether there is a
difference in primary patency and stent fracture between
two self-expandable nitinol stents with a different design
(SMART™ CONTROL versus COMPLETE™-SE) in sten-
otic or occlusive femoropopliteal arterial lesions. Fur-
thermore, the efficacy and safety between aspirin plus
clopidogrel versus aspirin plus cilostazol in patients
undergoing stent implantation in femoropopliteal lesions
will be evaluated. We hope to address these issues in the
SENS-FP trial, whereby we will enroll a large unselectedpopulation of patients treated with stent implantation





Binary restenosis: defined as a reduction in the luminal
diameter of >50% according to the worst angiographic
view at the narrowest site within the treated segment
plus the 10-mm segments proximal and distal to the
treated segment by catheter angiography or PSVR ≥2.5
(PSVR = peak systolic velocity within the area of stenosis
divided by peak systolic velocity in a normal adjacent
proximal artery segment) or total occlusion by duplex
ultrasound. Stent fracture rate according fracture grade
(minor, moderate, severe) [12]: plain X-ray examinations
for the stent fracture are used or performed using at
least two different angulations (30 to 45° difference) and
the highest available magnification. Stent fracture is classi-
fied as minor (single strut fracture), moderate (fracture of
more than 2 struts), or severe (complete separation of stent
segments). Target lesion revascularization (TLR): defined
as any repeat percutaneous intervention of the target lesion
or bypass surgery of the target vessel performed for resten-
osis because of a return of ischemic symptoms, decrease of
at least 1 Rutherford category, decrease in the ankle bra-
chial index of >0.15, or restenosis of >50% as measured by
catheter angiography. The target lesion is defined as the
treated segment from 10 mm proximal to the stent and to
10 mm distal to the stent. Target extremity revasculariza-
tion (TER): defined as any repeat percutaneous interven-
tion of the target extremity or bypass surgery of the target
extremity performed for restenosis because of a return of
ischemic symptoms, decrease of at least 1 Rutherford cat-
egory, decrease in the ankle brachial index of >0.15, or re-
stenosis of >50% as measured by catheter angiography.
Limb salvage: defined as survival free of amputation. Am-
putation is defined as above-ankle amputation of the index
limb. Sustained clinical improvement rate [36,37]: defined
as persistent ABI value ≥0.15 and persistent improvement
of ≥1 class according to Rutherford throughout follow-up
when compared with baseline without the need for repeat
TLR in surviving patients. Late loss: defined as a change in
MLD from final angiogram to follow-up. Major adverse
cardiac events (MACE): defined as composite of all-cause
death, myocardial infarction, cerebrovascular stroke, and
target lesion revascularization.
Immediate outcomes
Acute lesion success: defined as a residual stenosis of ≤30%
without flow-limiting dissection in the worst angiographic
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http://www.trialsjournal.com/content/15/1/355view. Definition of suboptimal result: residual pressure
gradient of >10 mmHg, residual stenosis of >30%, or
flow-limiting dissection. Acute hemodynamic success:
defined as a ≥ 0.15 improvement in the ankle-brachial
index from pre-procedure to immediately post-procedure
(discharge). Clinical success: defined as an improvement
of baseline symptoms by at least 1 Rutherford category
that was sustained throughout follow-up with no add-
itional intervention.QCA (Qualitative Comparative Analysis) data definition
and variables:
Reference vessel diameter (obtained from averaging 5-mm
segments proximal and distal to the lesion), minimal lu-
minal diameter (MLD), acute gain (change in MLD from
baseline to post-intervention), late loss (change in MLD
from the final angiogram to follow-up), percent diameter
stenosis, total reocclusion rate, and binary (>50%) resten-
osis rate [38].
Ankle-brachial index (ABI) calculation
Measurement of highest systolic pressure in both arms,
measurement of systolic pressure in both legs, use highest
ankle pressure (dorsalis pedis or posterior tibialis) for each
leg, and calculate ratio of each ankle to brachial pressure
by dividing each ankle by highest brachial pressure.
Bleeding and hemorrhagic complications
An episode of bleeding is defined by the TIMI (Thrombolysis
In Myocardial Infarction) criteria [39] as:
Major: overt clinical bleeding (or documented intra-
cranial or retroperitoneal hemorrhage) associated with a
drop in hemoglobin (Hgb) of greater than 5 g/dl (0.5 g/l)
or in hematocrit (Hct) of greater than 15% (absolute). A
patient who experiences an intracranial hemorrhage
should be considered to have a major hemorrhage.
Minor: overt clinical bleeding associated with a fall in
hemoglobin of 3 to less than or equal to 5 g/dl (0.5 g/l)
or in hematocrit of 9% to less than or equal to 15% (ab-
solute). None: no bleeding event that meets the major or
minor definition. In calculating the fall in hemoglobin or
hematocrit, a transfusion of whole blood or packed red
blood cells is counted as 1 g/dl (0.1 g/l) hemoglobin or
3% absolute in hematocrit. This would be in addition to
the actual fall in hemoglobin or hematocrit. To account
for transfusion, hemoglobin and hematocrit measure-
ments will be adjusted for any packed red blood cells or
whole blood given between baseline and post-transfusion
measurements. A transfusion of one unit of blood will be
assumed to result in an increase of 1 g/dL in Hgb or of 3%
in Hct. Thus, to calculate the true change in Hgb or Hct if
there has been an intervening transfusion between twoblood measurements, the following calculations should be
performed:
Hgb ¼ baseline Hgb : post transfusion Hgb½ 
þ number of transfused units½ 
Hct ¼ baseline Hct : post transfusion Hct½ 
þ number of transfused units  3½ 
The following will be classified as ‘instrumented’ major
bleeding that is considered to be associated with the
catheterization laboratory visit: major percutaneous
entry site: bleeding occurred at the percutaneous entry
site during or after the catheterization laboratory visit
until discharge. The bleeding should require a transfu-
sion and/or prolong the health care facility stay, and/or
cause a drop in Hgb >5 g/dL. Bleeding at the percutan-
eous entry site can be external or a hematoma >10 cm
for femoral access or >2 cm for radial access or >5 cm
for brachial access. major retroperitoneal, gastrointes-
tinal, genital, and urinary: bleeding occurred during or
after the catheterization laboratory visit until discharge.
The bleeding either requires surgical intervention (for
example, to relieve nerve compression), and/or requires
a transfusion and/or prolongs the health care facility
stay, and/or causes a drop in hemoglobin > 5.0 g/dL.
major other or unknown: bleeding occurred at other or
unknown locations during or after the catheterization la-
boratory visit until discharge. The bleeding should re-
quire a transfusion and/or prolong the healthcare facility
stay and/or cause a drop in Hgb > 5 g/dL.
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